MedPath

Accuracy of the New Barrett TAL Formula With the Argos Measurements: A Multicenter Prospective Study

Completed
Conditions
Cataract
Interventions
Device: Argos
Registration Number
NCT06085131
Lead Sponsor
Shammas Eye Medical Center
Brief Summary

This study is a prospective, multi-site, multi-surgeon, observational study of refractive accuracy with the Argos using BTAL after successful cataract surgery. Subjects will be assessed pre-operatively, operatively and at 5-8 weeks postoperatively. Clinical evaluations will include measurement of visual acuity, manifest refraction, and preoperative biometry.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
501
Inclusion Criteria

Subjects are eligible for the study if they meet the following criteria:

  • Cataract surgery that was completed without complications with biometry measured using the Argos biometer.
  • Subjects that elect Clareon SY60WF aspheric lens (Alcon, Fort Worth, TX).
  • Potential post-operative visual acuity of better than logMAR 0.30 (20/40).
  • BTAL was used to determine the IOL power implanted.
Exclusion Criteria

If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

  • Patients with pre-existing ocular pathology that in the opinion of the principial investigator would influence the postoperative refraction.
  • Any disease or pathology, including but not limited to irregular corneal astigmatism and keratoconus, that is expected to reduce the potential postoperative BCDVA to a level worse than 20/40.
  • Patients with history of previous ocular surgery.
  • Patients with signs of inability to understand consent for study and procedure planned.
  • Eyes with intraoperative or postoperative complications.
  • Suboptimal surgical outcomes that are not related to the treatment plan, e.g. capsular tear, cystoid macular edema.
  • Astigmatism >±0.75D.

Each investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Argos BiometerArgosPreoperative biometry with the Argos device
Primary Outcome Measures
NameTimeMethod
The percentage of eyes that achieve a postoperative manifest spherical equivalent refraction ≤ ±0.50 D.2 months postoperative
Secondary Outcome Measures
NameTimeMethod
The Mean Predictive Error and its standard deviation after constant personalization for the entire series.2 months postoperative
The Mean Predictive Errors in the short eyes and in the long eyes2 months postoperative

The Mean Predictive Errors in the short eyes and in the long eyes (Short AL\<22.5mm, Long AL \>24.5mm and Medium AL 22.6mm to 24.4mm), and the percentage of eyes that achieve a postoperative manifest spherical equivalent refraction ≤ ±0.25 D, ≤ ±0.50 D, ≤ ±0.75 D and ≤ ±1.00 D in each of these categories.

The percentage of eyes that achieve a postoperative manifest spherical equivalent refraction ≤ ±0.250D, ≤ ±0.75D and ≤ ±1.00D.2 months postoperative

Trial Locations

Locations (6)

Colvard-Kandavel Eye Center

🇺🇸

Encino, California, United States

Shammas Eye Medical Center

🇺🇸

Lynwood, California, United States

Shammas Eye Center

🇺🇸

Whittier, California, United States

Multack Eye Care, Sc

🇺🇸

Frankfort, Illinois, United States

Multack Eye Care, SC

🇺🇸

Olympia Fields, Illinois, United States

Juliette Eye Institute

🇺🇸

Albuquerque, New Mexico, United States

© Copyright 2025. All Rights Reserved by MedPath